Article info

Original research
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells

Authors

  1. Correspondence to Dr Thomas R Malek; tmalek{at}med.miami.edu
View Full Text

Citation

LaPorte KM, Hernandez R, Santos Savio A, et al
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells

Publication history

  • Accepted May 16, 2023
  • First published June 2, 2023.
Online issue publication 
June 02, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.